Biotech · Public company · Salt Lake City, UT, US
Myriad Genetics Inc
Ticker MYGN · SEC CIK 0000899923
Track this companyFree. Adds Myriad Genetics Inc to your Dealase workspace and tells you when its record changes.
Clinical trials144 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Clinical trials14
- Trial of Combined Obstetric Carrier Screening and Hereditary Cancer ScreeningNA · RECRUITING · started Sep 2, 2025ClinicalTrials.gov NCT07052266 · fetched Nov 12, 2026
- SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 17, 2023ClinicalTrials.gov NCT05642780 · fetched Nov 12, 2026
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem CellsPHASE1 · RECRUITING · started Jan 13, 2021ClinicalTrials.gov NCT04150042 · fetched Nov 12, 2026
- Genetic Testing for All Breast Cancer Patients (GET FACTS)NA · COMPLETED · started Jan 31, 2020ClinicalTrials.gov NCT04245176 · fetched Nov 12, 2026
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1 · COMPLETED · started Jun 28, 2017ClinicalTrials.gov NCT03150810 · fetched Nov 12, 2026
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)PHASE3 · COMPLETED · started Feb 6, 2017ClinicalTrials.gov NCT02987543 · fetched Nov 12, 2026
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 11, 2016ClinicalTrials.gov NCT02655016 · fetched Nov 12, 2026
- A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy RegimensPHASE2 · COMPLETED · started Mar 23, 2015ClinicalTrials.gov NCT02354586 · fetched Nov 12, 2026
- Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian CancerPHASE1_PHASE2 · COMPLETED · started Feb 15, 2015ClinicalTrials.gov NCT02354131 · fetched Nov 12, 2026
- Genetic Evaluation of Men (GEM)TERMINATED · started Oct 23, 2014ClinicalTrials.gov NCT03076242 · fetched Nov 12, 2026
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)PHASE3 · COMPLETED · started Apr 7, 2014ClinicalTrials.gov NCT01968213 · fetched Nov 12, 2026
- Cisplatin vs Paclitaxel for Triple Negative Breast CancerPHASE2 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT01982448 · fetched Nov 12, 2026
- A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)PHASE2 · COMPLETED · started Oct 30, 2013ClinicalTrials.gov NCT01891344 · fetched Nov 12, 2026
- A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian CancerPHASE3 · COMPLETED · started Jun 21, 2013ClinicalTrials.gov NCT01847274 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 16, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 23, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026